Clinical Trial

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-27; most recent amendment 2026-02-06.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-11-12
Trial Details
NCT Number NCT07156578
Lead Sponsor Rhythm Pharmaceuticals, Inc.
Conditions Hypothalamic Obesity
Enrollment 25 participants
Start Date 2025-11-10
Primary Completion 2028-04-15 (estimated)
Study Completion 2028-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-10